An endocrinologist at an academic diabetes center described the same conversation recurring roughly twice a month by late 2025: a patient with fifteen or twenty years of type 1 diabetes, an insulin pump, a reasonable A1c, and a BMI above 32, asking whether tirzepatide (Mounjaro, Zepbound) could be added to the regimen. Tirzepatide is not approved for type 1 diabetes. No pivotal trial supporting its original approvals enrolled anyone with absolute insulin deficiency. Yet by 2026 a first randomized phase 2 trial, several retrospective cohorts, and two phase 3 programs exist alongside case reports of euglycemic diabetic ketoacidosis tied directly to off-label tirzepatide use in this population. The evidence is recent, encouraging on weight and insulin dose, and unresolved on safety.
Off-Label Status: What FDA Approval Actually Covers
Tirzepatide received its first FDA approval in May 2022 as Mounjaro, indicated as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes, with a cardiovascular risk-reduction indication added later for adults with type 2 diabetes at elevated cardiovascular risk (FDA prescribing information). The same molecule received a separate approval as Zepbound in late 2023 for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. Neither label references type 1 diabetes, and no phase 3 program supporting either approval enrolled participants with absolute insulin deficiency.
That gap is deliberate, not an oversight. A type 1 diabetes program requires safety infrastructure the SURPASS and SURMOUNT trials did not build: ketone monitoring, hypoglycemia adjudication committees, and insulin-dose protocols suited to a population with zero endogenous insulin reserve. Prescribing tirzepatide to a patient with type 1 diabetes is legal and increasingly common in endocrinology practice, but it remains entirely off-label, which means the prescriber — not the FDA — has reviewed the risk-benefit tradeoff for this specific use.
Off-label status also shapes access. Many payers deny coverage outside the approved indication, pushing patients toward cash pay in the $1,000–$1,300 per month range or toward compounded versions during documented shortages. The stability and sterility profile of compounded incretin products differs meaningfully from the FDA-approved pen, a distinction examined for the related molecule semaglutide in a companion analysis of compounded semaglutide versus FDA-approved brands; the same sourcing considerations apply to compounded tirzepatide used off-label in type 1 diabetes.
The Mechanistic Case for a GIP/GLP-1 Coagonist in Absolute Insulin Deficiency
Type 1 diabetes is conventionally framed as a disease of missing insulin, but the postprandial glucose excursions clinicians manage daily are driven as much by glucagon dysregulation. Alpha cells in type 1 diabetes fail to suppress glucagon after an oral glucose load even though they can still suppress it after an intravenous glucose load — a dissociation pointing to a defect in gut-level incretin signaling rather than an intrinsic alpha-cell failure. That observation is the pharmacological opening for incretin-based adjunct therapy in a population otherwise defined by beta-cell loss.
Tirzepatide binds and activates both the GIP receptor and the GLP-1 receptor; molecular pharmacology work describes it as a 39-amino-acid synthetic peptide built on a GIP backbone with a C20 fatty di-acid moiety for albumin binding and extended half-life (Coskun et al., Molecular Metabolism, 2018). The combined agonism suppresses glucagon secretion in a glucose-dependent manner, slows gastric emptying, and reduces caloric intake through central appetite pathways — mechanisms detailed further in a broader review of GLP-1 receptor mechanism of action and tolerability. None of those pathways require intact beta-cell function, which is why the drug class was theoretically plausible in type 1 diabetes before anyone tested it in a randomized trial.
The same slowed gastric emptying that blunts postprandial glucose spikes also delays absorption of rapid-acting insulin and oral carbohydrate used to correct hypoglycemia — a timing mismatch that becomes clinically important in the ketoacidosis discussion below.
TIRTLE1: The First Randomized Controlled Trial Data
The first placebo-controlled trial of tirzepatide in type 1 diabetes, TIRTLE1, enrolled 24 adults (12 per arm) with type 1 diabetes and BMI above 30 kg/m², randomized to once-weekly subcutaneous tirzepatide — 2.5 mg for four weeks, then 5.0 mg for eight weeks — or placebo, with a 12-week primary endpoint (ACTRN12624000111572; Diabetes Care 2026;49(1):161–170, PMID 41264593). This is a phase 2, hypothesis-generating trial, not a registration study, and its 5 mg dose ceiling sits well below the 15 mg maximum used in type 2 diabetes and obesity programs.
Body weight fell 10.3 kg in the tirzepatide group versus 0.7 kg with placebo, an estimated treatment difference of −8.7 kg over 12 weeks. Total daily insulin dose dropped 24.2 units/day with tirzepatide versus 0.3 units/day with placebo, a 35.1% relative reduction compared with placebo (total daily dose p=0.0002; basal insulin p=0.002; bolus insulin p=0.008). On a patient-reported treatment satisfaction measure, 100% of the tirzepatide group felt the treatment addressed their diabetes-management needs, versus 37.5% on placebo.
The trial was not powered to detect a difference in HbA1c or time in range, and 12 weeks is too short to assess durability or long-term ketoacidosis risk with only 24 participants. What it demonstrates is proof of pharmacologic concept: weight loss and insulin-dose reduction comparable in magnitude to tirzepatide's effect in type 2 diabetes, in a population where that effect had never been formally tested.
What's Still Enrolling: TZP-T1D, SURPASS-T1D-1, and the Phase 3 Pipeline
Three larger trials are underway or have recently completed enrollment. TZP-T1D (NCT06180616) is an investigator-initiated, double-blind, placebo-matched trial randomizing 60 adults with type 1 diabetes and overweight or obesity (BMI ≥27 kg/m², HbA1c ≤10%) 1:1 to tirzepatide titrated to a 15 mg maximum tolerated dose or placebo over 32 weeks, with six months of post-treatment follow-up. The primary endpoint is percent body-weight change; secondary endpoints include HbA1c, time in range, insulin dose, lipids, blood pressure, renal markers, arterial stiffness, and quality-of-life scores. The sample size was powered on retrospective data showing roughly 23% weight reduction, with 15% dropout built into the calculation.
SURPASS-T1D-1 (NCT06914895) is the first Lilly-sponsored phase 3 program in this population — a multicenter, double-blind, placebo-controlled trial testing four tirzepatide dose arms against placebo in adults with type 1 diabetes and overweight or obesity. As of mid-2026 it is listed as active, not recruiting, meaning enrollment has closed and results are pending. A companion extension (NCT06820281), sponsored by the Garvan Institute, is following the TIRTLE1 cohort for longer-term metabolic outcomes.
Separately, three trials of semaglutide as adjunct therapy in type 1 diabetes (NCT03899402, NCT05819138, NCT05822609) are running in parallel, reflecting a broader incretin-class question rather than one specific to tirzepatide. For context on how tirzepatide's dual-agonist profile compares with semaglutide's single-receptor mechanism where head-to-head data already exist, see the SURMOUNT-5 head-to-head trial data.
Real-World Signal: Retrospective Cohorts and a Six-Study Meta-Analysis
Observational data arrived before the phase 3 results. A propensity-score-matched retrospective cohort from two Australian endocrinology centers compared 23 adults with type 1 diabetes started on tirzepatide against 23 matched controls, with mean follow-up of 28–31 weeks. Participants averaged 45 years old with roughly 23–24 years of diabetes duration, a baseline BMI near 35 kg/m², and 74% were using insulin pumps. Body weight fell 10.01% in the tirzepatide group versus a 0.69% gain in controls; total daily insulin dropped 21.82 units/day versus an increase of 5.62 units/day in controls. HbA1c fell 0.37% versus 0.02%, though the difference did not reach significance after adjustment, while glucose variability (standard deviation) improved significantly (−0.24 vs. +0.16 mmol/L, p=0.022).
A 2026 systematic review and meta-analysis pooled six observational studies totaling 248 adults with type 1 diabetes and overweight or obesity. At six months, tirzepatide adjunct therapy was associated with an HbA1c reduction of 0.61 percentage points (95% CI −0.69 to −0.52), weight loss of 9.9 kg (95% CI −10.46 to −9.35), BMI reduction of 8.3 kg/m² (95% CI −9.92 to −7.31), and a total daily insulin reduction of 23.73 units/day (95% CI −25.36 to −22.11), split roughly 8.71 units/day basal and 15.02 units/day bolus.
These are observational, not randomized, effect sizes — confounded by indication and by the likelihood that patients motivated enough to pursue off-label therapy also intensify self-management. They are directionally consistent with TIRTLE1, which strengthens confidence in the weight and insulin-sparing signal even as the glycemic and safety picture remains unsettled.
The DKA Problem: What ADJUNCT ONE Taught Clinicians About Incretins in Type 1 Diabetes
Tirzepatide is not the first incretin-based adjunct tested in type 1 diabetes, and earlier data set the safety framework clinicians still use. ADJUNCT ONE randomized 1,398 adults with type 1 diabetes 3:1 to liraglutide (1.8, 1.2, or 0.6 mg daily) or placebo on top of insulin for 52 weeks (NCT01836523; Mathieu et al., Diabetes Care, 2016, PMID 27506222). Liraglutide 1.2 mg and 1.8 mg produced HbA1c reductions of 0.54 and 0.49 percentage points versus placebo, with meaningful weight loss and lower total daily insulin dose. But symptomatic hypoglycemia rose to 16.5 events per patient-year on the 1.8 mg dose versus 12.3 on placebo, and hyperglycemia with ketosis occurred in 11.2% of the 1.8 mg group versus 6.9% on placebo. Eight confirmed cases of diabetic ketoacidosis occurred during the trial, all in C-peptide-negative participants, typically triggered by intercurrent infection, insulin pump failure, or a prior DKA history.
The mechanistic read-through to tirzepatide is direct. Any agent that suppresses appetite, slows gastric emptying, and lowers insulin requirement in someone with zero endogenous insulin reserve removes a safety margin present in type 2 diabetes but absent in type 1 diabetes. Residual beta-cell function in type 2 diabetes provides a backstop against ketosis even when insulin dosing is reduced too aggressively; in type 1 diabetes, there is no backstop. Insulin omission or under-dosing combined with reduced appetite can progress to ketoacidosis within hours, and delayed gastric emptying can mask early warning symptoms, a point explored further in the mechanism of GLP-1 receptor agonists and gastric emptying.
Case Reports: Euglycemic DKA Specifically Tied to Tirzepatide
Beyond the liraglutide trial data, published case reports describe diabetic ketoacidosis occurring specifically after tirzepatide initiation in people with type 1 diabetes, generally in the euglycemic or near-euglycemic range — a presentation that is easy to miss because glucose values look reassuring while ketones accumulate. One report describes a patient with type 1 diabetes who developed severe euglycemic DKA requiring intubation and intravenous bicarbonate after starting tirzepatide while already on an SGLT2 inhibitor and basal-bolus insulin, treated at a tertiary center in Karachi, Pakistan (PMID 41584389). A second case report documents tirzepatide-associated euglycemic DKA in a patient with type 1 diabetes with no SGLT2 inhibitor involved at all, indicating the coagonist itself — not only an SGLT2 inhibitor interaction — can precipitate the event (PMID 41747466).
Case reports are the lowest tier of clinical evidence and cannot establish incidence; a handful of published cases says nothing about the denominator of off-label tirzepatide users with type 1 diabetes who did not develop DKA. But they establish plausibility and a specific mechanism of harm — appetite suppression leading patients to reduce meals and, in parallel, to reduce or skip insulin doses without recognizing that basal insulin requirements persist independent of caloric intake. Combined with the eight DKA cases from ADJUNCT ONE, the signal is consistent enough that ongoing trial protocols, including TZP-T1D and SURPASS-T1D-1, mandate ketone meter access and explicit sick-day insulin instructions as a condition of enrollment.
A Monitoring Framework for Off-Label Use
Trial protocols for tirzepatide in type 1 diabetes converge on a similar safety architecture, which illustrates how off-label use is being managed in practice even though none of this constitutes a formal clinical guideline. Continuous glucose monitoring is required in both TZP-T1D and the TIRTLE program, and participants are provided a home blood ketone meter rather than relying on urine strips alone, since blood beta-hydroxybutyrate rises earlier and more reliably than urine ketones during evolving ketoacidosis. Severe hypoglycemia within the prior three months is an exclusion criterion in TZP-T1D, reflecting concern that stacking a glucagon-suppressing agent onto a hypoglycemia-prone regimen compounds risk in both directions.
Dose titration in every published or registered protocol is slower than the type 2 diabetes label: TIRTLE1 capped dosing at 5 mg after eight weeks, and TZP-T1D titrates toward 15 mg only as tolerated, with explicit allowance to hold or reduce the dose for gastrointestinal intolerance. Insulin dose adjustment in these protocols is proactive rather than reactive — basal and bolus doses are reduced incrementally as appetite and glucose trends change, rather than waiting for hypoglycemia to force a correction, and patients are instructed never to omit basal insulin entirely regardless of reduced food intake.
Body composition tracking also appears in several protocols, reflecting a broader concern with GLP-1-class weight loss: a meaningful fraction of weight lost on incretin therapy is lean mass rather than fat mass, a dynamic reviewed for the GLP-1 class generally in research on preserving lean muscle during rapid GLP-1-associated weight loss, which carries added relevance in type 1 diabetes given the elevated sarcopenia risk already documented in long-duration disease.
What the Evidence Still Doesn't Answer
The published record on tirzepatide in type 1 diabetes covers 12 to 32 weeks of exposure in trials totaling fewer than 100 randomized participants, plus a handful of retrospective cohorts and case reports. Several questions remain open. Durability is unknown — whether weight loss and insulin-dose reduction persist beyond six to eight months, or whether discontinuation produces a regain pattern similar to that documented for the GLP-1 class more broadly, a question examined in long-term follow-up of GLP-1 discontinuation and weight regain.
DKA incidence in a larger, adequately powered sample is unknown; TIRTLE1 and the retrospective Australian cohort reported zero DKA events each, but both were small, closely monitored, and enrolled patients with reasonably well-controlled baseline disease — not the broader population with brittle glycemic control or limited CGM access who might pursue the drug off-label in community practice. Pediatric and adolescent data do not exist. Interaction risk with SGLT2 inhibitors, increasingly co-prescribed off-label in type 1 diabetes for renal and cardiovascular benefit, has only been documented in isolated case reports rather than studied systematically. No trial has yet reported severe hypoglycemia rates specifically, despite that being the dominant adverse signal with liraglutide in ADJUNCT ONE. SURPASS-T1D-1's phase 3 results, once reported, are the first dataset positioned to address several of these gaps at a scale that matters.
For a patient with type 1 diabetes considering tirzepatide today, the concrete next step is not a prescription request but a structured conversation with an endocrinologist about trial eligibility — TZP-T1D, SURPASS-T1D-1's successor studies, and the Dasman Diabetes Institute program (NCT07096908) are actively enrolling in some regions — or, if off-label use proceeds outside a trial, a documented sick-day protocol, home blood ketone testing, and a plan for insulin dose adjustment agreed on before the first dose rather than after the first episode of nausea.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.